Hostname: page-component-77c89778f8-gq7q9 Total loading time: 0 Render date: 2024-07-20T21:15:28.962Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmaceutical Marketing Practices: Pharmaceutical Companies Facing Competition from Generic Drug Manufacturers May Face Increased Scrutiny for Anticompetitive Marketing Practices—In re Warfarin Sodium Antitrust Litig.

Published online by Cambridge University Press:  06 January 2021

Karen Brooks
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Select Recent Court Decisions
Information
American Journal of Law & Medicine , Volume 31 , Issue 2-3 , June 2005 , pp. 381 - 383
Copyright
Copyright © American Society of Law, Medicine and Ethics and Boston University 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 391 F.3d 516 (3d Cir. 2004).

2 Id.

3 Id. at 521. More than two million Americans take warfarin sodium to treat blood-clot disorders. Id. at 523. Although DuPont's patent expired in 1962, DuPont has continued to be the dominant manufacturer and supplier of warfarin sodium under the Coumadin brand name. Id. In 1998 and 1999, DuPont recorded sales of warfarin sodium reaching approximately $550 million and $464 million. Id.

4 Id. at 521.

5 Id. at 522.

6 Id. at 522-23.

7 Id. at 523.

8 Id.

9 Id. The publicity campaign emphasized Barr's decision to make a cheaper product for purely monetary reasons and cited DuPont's concerns with patient safety. See 3D Cir. Affirms DuPont's $44.5 Million Coumadin Settlement, 12 NO. 9 Andrews Health L. Litig. Rep. 11, 11 (2005)Google Scholar.

10 In re Warfarin Sodium Antitrust Litig., 391 F.3d at 523.

11 Id.

12 Id.

13 Id.

14 Id.

15 Id. at 524.

16 Id. at 525.

17 Id.

18 Id.

19 Id. at 527.

20 See 3D Cir. Affirms DuPont's $44.5 Million Coumadin Settlement, supra note 9.

21 In re Warfarin Sodium Antitrust Litig., 391 F.3d at 528.

22 Id. at 529.

23 Id. at 528 (quoting Amchem Prods., Inc. v. Windsor, 521 U.S. 591, 625 (1997)).

24 Id. at 530 (discussing rulings in In re Lorazepam & Clorazepate Antitrust Litig., 205 F.R.D. 369 (D.D.C. 2002), and In re Sythroid Mktg. Litig., 188 F.R.D. 295 (N.D. Ill. 1999)).